Table 4.

Contribution of each component of costs due to TB diagnosis as a proportion of total costs, stratified by Axshya SAMVAD and non-Axshya SAMVAD groups, among patients with new sputum-smear-positive TB enrolled in Axshya SAMVAD study in India, 2016–2017 (N = 465).

	Overall (N = 465)	Axshya SAMVAD (N = 234)	Non-Axshya SAMVAD (N = 231)
Costs due to TB diagnosis as a proportion of total costs	%	%	%
Total costs	100	100	100
Direct medical costs	83.3	80.8	84.7
Consultation fee	12.6	13.0	12.3
Medicines	59.3	59.2	59.3
Investigations	11.5	8.6	13.1
Direct non-medical costs (Travel)	11.4	15.7	9.1
Direct costs	94.7	96.5	93.8
Indirect costs (Wages/income lost)	5.3	3.5	6.2

Column percentage.

SAMVAD: sensitisation and advocacy in marginalised and vulnerable areas of the district. Axshya SAMVAD: an active case finding strategy under project Axshya implemented by The Union, South East Asia office, New Delhi, India, across 285 districts of India. Non-Axshya SAMVAD: patients detected through passive case findings.

Total costs information was available from all 465. However, details of time spent in consultation and costs for consultation, medicines, investigations and travel were not available for 11 patients.